{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:42:46Z","timestamp":1791139366731,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T00:00:00Z","timestamp":1133222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s11307-005-0023-2","type":"journal-article","created":{"date-parts":[[2005,11,28]],"date-time":"2005-11-28T18:00:12Z","timestamp":1133200812000},"page":"43-48","source":"Crossref","is-referenced-by-count":160,"title":["Positron Emission Tomography\/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5\u00a0ng\/ml?"],"prefix":"10.1007","volume":"8","author":[{"given":"Martin","family":"Heinisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Dirisamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Loidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Stoiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gruy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Haim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Langsteger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,11,29]]},"reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910\u2013914","journal-title":"J Urol"},{"key":"23_CR2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.urology.2004.01.010","volume":"63","author":"AM Kamat","year":"2004","unstructured":"Kamat AM, Rosser CJ, Levy LB, et al. (2004) Rise in serum PSA of 1.5\u00a0ng\/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63:1132\u20131137","journal-title":"Urology"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","volume":"163","author":"JW Moul","year":"2000","unstructured":"Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163:1632\u20131642","journal-title":"J Urol"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s002619900079","volume":"21","author":"RA Huch Boni","year":"1996","unstructured":"Huch Boni RA, Meyenberger C, Pok Lundquist J, Trinkler F, Lutolf U, Krestin GP (1996) Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imaging 21:345\u2013352","journal-title":"Abdom Imaging"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1148\/radiology.219.2.r01ma20432","volume":"219","author":"AK Leventis","year":"2001","unstructured":"Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219:432\u2013439","journal-title":"Radiology"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022627421000","volume":"20","author":"MP Roudier","year":"2003","unstructured":"Roudier MP, Vesselle H, True LD, et al. (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171\u2013180","journal-title":"Clin Exp Metastasis"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0090-4295(94)90180-5","volume":"43","author":"AW Partin","year":"1994","unstructured":"Partin AW, Pearson JD, Landis PK, et al. (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649\u2013659","journal-title":"Urology"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1097\/01.ju.0000127734.01845.99","volume":"171","author":"OT Okotie","year":"2004","unstructured":"Okotie OT, Aronson WJ, Wieder JA, Liao Y, et al. (2004) Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260\u20132264","journal-title":"J Urol"},{"key":"23_CR9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0302-2838(03)00207-0","volume":"44","author":"IJ Jong de","year":"2003","unstructured":"de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32\u201338","journal-title":"Eur Urol"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","volume":"169","author":"M Picchio","year":"2003","unstructured":"Picchio M, Messa C, Landoni C, et al. (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169:1337\u20131340","journal-title":"J Urol"},{"key":"23_CR11","first-page":"92","volume":"43","author":"TR DeGrado","year":"2002","unstructured":"DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92\u201396","journal-title":"J Nucl Med"},{"key":"23_CR12","first-page":"110","volume":"61","author":"TR DeGrado","year":"2001","unstructured":"DeGrado TR, Coleman RE, Wang S, et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61:110\u2013117","journal-title":"Cancer Res"},{"key":"23_CR13","first-page":"1805","volume":"42","author":"TR DeGrado","year":"2001","unstructured":"DeGrado TR, Baldwin SW, Wang S, et al. (2001) Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805\u20131814","journal-title":"J Nucl Med"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","volume":"168","author":"DT Price","year":"2002","unstructured":"Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273\u2013280","journal-title":"J Urol"},{"key":"23_CR15","first-page":"187","volume":"43","author":"T Hara","year":"2002","unstructured":"Hara T, Kosaka N, Kishi H (2002) Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187\u2013199","journal-title":"J Nucl Med"},{"key":"23_CR16","unstructured":"Vassiliev D, Krasikova R, Kutznetsova O, Federova O, Nader M (2003) Simple HPLC Method for the Detection of N,N-dimethylaminoethanol in the Preparation of [N-m ethyl-11C]Choline [abstract]. Eur J Nucl Med 30(suppl):342P"},{"key":"23_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.semnuclmed.2004.03.006","volume":"34","author":"D Delbeke","year":"2004","unstructured":"Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209\u2013223","journal-title":"Semin Nucl Med"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1095-0397(00)00082-0","volume":"3","author":"A Maldonado","year":"2000","unstructured":"Maldonado A, Sancho F, Cerdan J, et al. (2000) FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level. Experience in 72 patients. Clin Positron Imaging 3:170","journal-title":"Clin Positron Imaging"},{"key":"23_CR19","first-page":"1464","volume":"42","author":"BO Helal","year":"2001","unstructured":"Helal BO, Merlet P, Toubert ME, et al. (2001) Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464\u20131469","journal-title":"J Nucl Med"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000019923","volume":"36","author":"C Hofer","year":"1999","unstructured":"Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36:31\u201335","journal-title":"Eur Urol"},{"key":"23_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/MCB.9.1.325","volume":"9","author":"IG Macara","year":"1989","unstructured":"Macara IG (1989) Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 9:325\u2013328","journal-title":"Mol Cell Biol"},{"key":"23_CR22","first-page":"331","volume":"44","author":"IJ Jong de","year":"2003","unstructured":"de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44:331\u2013335","journal-title":"J Nucl Med"},{"key":"23_CR23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.ju.0000142099.80156.85","volume":"173","author":"SA Kwee","year":"2005","unstructured":"Kwee SA, Coel MN, Lim J, Ko JP (2005) Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 173:252\u2013255","journal-title":"J Urol"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jjco\/hyf052","volume":"32","author":"CS Liu","year":"2002","unstructured":"Liu CS, Shen YY, Lin CC, Yen RF, Kao CH (2002) Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32:244\u2013247","journal-title":"Jpn J Clin Oncol"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1464-410X.2004.04927.x","volume":"94","author":"P Gomez","year":"2004","unstructured":"Gomez P, Manoharan M, Kim SS, Soloway MS (2004) Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94:299\u2013302","journal-title":"BJU Int"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00066-004-1208-3","volume":"180","author":"C Menzel","year":"2004","unstructured":"Menzel C, Dobert N, Hamscho N, et al. (2004) The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 180:497\u2013501","journal-title":"Strahlenther Onkol"},{"key":"23_CR27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncr.20349","volume":"101","author":"TC Chang","year":"2004","unstructured":"Chang TC, Law KS, Hong JH, et al. (2004) Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 101:164\u2013171","journal-title":"Cancer"},{"key":"23_CR28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1095-0397(00)00059-5","volume":"3","author":"R Coleman","year":"2000","unstructured":"Coleman R, DeGrado T, Wang S, et al. (2000) Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3:147","journal-title":"Clin Positron Imaging"},{"key":"23_CR29","unstructured":"Heinisch M, Meier S, Salomon U, Panholzer PJ, Stoiber P, Langsteger W (2004) Initial experience in F18-fluorocholine PET\/CT in prostate cancer\u2014implications for the determination of a PET\/CT acquisition protocol. Q J Nucl Med Mol Imaging 48(suppl):7P"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-005-0023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-005-0023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-005-0023-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T13:37:41Z","timestamp":1559396261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-005-0023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11307-005-0023-2","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,29]]}}}